BlackThorn Therapeutics
Signal active
Organization
Contact Information
Overview
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
About
Industries
Biotechnology, Artificial Intelligence (AI), Health Care, Therapeutics
Founded
2015
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
BlackThorn Therapeutics headquartered in United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $8.8B in funding across 64 round(s). With a team of 11-50 employees, BlackThorn Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - BlackThorn Therapeutics, raised $40.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
5
Lead Investors
0
Total Funding Amount
$138.0M
Details
3
BlackThorn Therapeutics has raised a total of $138.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 76.0M | ||
| 2017 | Early Stage Venture | 14.0M | ||
| 2016 | Early Stage Venture | 40.0M |
Investors
BlackThorn Therapeutics is funded by 29 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Danny Janiak | - | FUNDING ROUND - Danny Janiak | 40.0M |
| Mercury | - | FUNDING ROUND - Mercury | 40.0M |
| BlackThorn Therapeutics | - | FUNDING ROUND - BlackThorn Therapeutics | 40.0M |
| Alexandria Real Estate Equities | - | FUNDING ROUND - Alexandria Real Estate Equities | 40.0M |
Recent Activity
There is no recent news or activity for this profile.